Tumour markers requesting pattern with regards to different organizational settings in Italy: A survey of hospital laboratories

Annals of Clinical Biochemistry

Volumn 46, Issue 4, 2009, Pages 316-321

  Franceschini, Roberta ^a   Trevisiol, Chiara ^a   Dittadi, Ruggero ^b   Gion, Massimo ^a,b,c  

^a Association ABO for the Application of Biotechnologies in Oncology   (Italy)

^b Unit of Laboratory Medicine   (Italy)

^c Regional Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ARTICLE; HEALTH CARE ORGANIZATION; HOSPITAL BED; HOSPITAL DEPARTMENT; HOSPITAL LABORATORY; HOSPITAL PATIENT; ITALY; LABORATORY TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; SAMPLE SIZE;

HEALTH CARE SURVEYS; HUMANS; ITALY; QUESTIONNAIRES; TUMOR MARKERS, BIOLOGICAL;

EID: 67650806480     PISSN: 00045632     EISSN: 00045632     Source Type: Journal    
DOI: 10.1258/acb.2009.008240     Document Type: Article

References (12)

1. Duffy MJ. Evidence for the clinical use of tumour markers. Ann Clin Biochem 2004;41:370-377 (Pubitemid 39279922)
2. Loi S, Haydon AM, Shapiro J, Schwarz MA, Schneider HG. Towards evidence-based use of serum tumour marker requests: an audit of use in a tertiary hospital. Intern Med J 2004;34:545-550 (Pubitemid 39482329)
3. Arioli D, Pipino M, Boldrini E, et al. Tumour markers in internal medicine: a low-cost test or an unnecessary expense? A retrospective study based on appropriateness. Intern Emerg Med 2007;2:88-94
4. McDonnell M. An audit of tumour marker requests in Northern Ireland. Ann Clin Biochem 2004;41:378-384 (Pubitemid 39279923)
5. Gion M, Barioli P, Ponti A, Torri V, Mione R, Dittadi R. How tumour markers are used in the routine follow-up of breast and colorectal cancer. A survey of 29 Italian hospitals. Int J Biol Markers 1998;13:124-138 (Pubitemid 29092521)
6. Gion M, Mione R, Dittadi R, Gatti C, Bruscagnin G. Marcatori tumorali circolanti: importanza di un corretto impiego nel bilancio costo/ beneficio. Argomenti di Oncologia 1989;10:423-430
7. Gion M, Rampazzo A, Mione R, Bruscagnin G. Cost/effectiveness ratio of carcinoembryonic antigen-importance of adequacy of routine requests of tumour markers. Int J Biol Markers 1992;7:179-188
8. Ciatto S. Prostate-specific antigen: appropriate and inappropriate use. Recenti Prog Med 2003;94:95-98 (Pubitemid 36934847)
9. Clinical practice guidelines for the use of tumour markers in breast and colorectal cancer. J Clin Oncol 1996;14:2843-2877
10. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumour markers in breast cancer. J Clin Oncol 2007;25:5287-5312
11. Sturgeon C. Practice guidelines for tumor marker use in the clinic. Clin Chem 2002;48:1151-1159 (Pubitemid 34809819)
12. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA 2003;289:1414-1420